De Placido S, Gallo C, Marinelli A, Perrone F, Pagliarulo C, Petrella G, Delrio G, D'Istria M, Del Mastro L, Bianco A R
Division of Medical Oncology, University of Naples Medical School II, Italy.
Breast Cancer Res Treat. 1990 Sep;16(2):111-7. doi: 10.1007/BF01809295.
Ten year disease-free survival (DFS) results of the Naples randomized trial of adjuvant tamoxifen (TM), 30 mg per day for 2 years versus no therapy according to receptor levels, are reported. From Feb. 1, 1978, through Dec. 31, 1983, 308 pre- and postmenopausal patients with early breast cancer entered the trial. Estrogen receptor (ER) data were available on 239 (77.6%) patients, progesterone receptor (PgR) data on 194 (63.0%), and both receptor data on 181 (58.8%). ER and PgR were assayed by dextran-coated charcoal technique in a single laboratory. The effect of adjuvant TM was significantly related to ER and PgR concentration of the primary tumor. The greatest TM benefit on DFS was evident in patients with the highest levels of receptors. The interaction between the treatment effect and receptor concentration was found whether ER and PgR were considered separately or together.
报告了那不勒斯辅助性他莫昔芬（TM）随机试验的十年无病生存率（DFS）结果，该试验中根据受体水平，将患者分为每天服用30毫克TM持续2年组与不接受治疗组。从1978年2月1日至1983年12月31日，308例绝经前和绝经后早期乳腺癌患者进入该试验。239例（77.6%）患者有雌激素受体（ER）数据，194例（63.0%）有孕激素受体（PgR）数据，181例（58.8%）两者数据均有。ER和PgR在单个实验室通过葡聚糖包被活性炭技术进行检测。辅助性TM的效果与原发肿瘤的ER和PgR浓度显著相关。在受体水平最高的患者中，TM对DFS的益处最为明显。无论单独考虑ER和PgR还是将它们一起考虑，均发现治疗效果与受体浓度之间存在相互作用。
